Disclosures: Isaac Benque: Nothing to Disclose, Arielle Klepper: Nothing to Disclose, Michael Li: Nothing to Disclose, Gerardo Rubio Monroy: Nothing to Disclose, Swathi Kari: Nothing to Disclose, Melawit Tekeste: Nothing to Disclose, Javier Castro: Nothing to Disclose, Briton Lee: Nothing to Disclose, Mandana Khalili: gilead sciences: Grant/Research Support, GSK pharmaceuticals: Consultant, Intercept pharmaceuticals: Grant/Research Support, Gilead Sciences Inc: Consultant, Jennifer Price: Nothing to Disclose, Emily Perito: Mirum: Consultant, Ultragenyx: Consultant, BridgeBio: Consultant, Amagma: Consultant, Mirum: Grant/Research Support, Albireo: Grant/Research Support, Gilead: Grant/Research Support, Dicerna: Grant/Research Support, Sandy Feng: Nothing to Disclose, Jacquelyn Maher: Nothing to Disclose, Jennifer Lai: Nestle Nutrition Institute: Grant/Research Support, Novo Nordisk: Consultant, Genfit: Consultant, Boehringer Ingelheim: Advisor, POSULD Team: Nothing to Disclose, Joseph DeRisi: Nothing to Disclose, Michele Tana: Nothing to Disclose 2406 PERFORMANCE OF URSODEOXYCHOLIC ACID RESPONSE SCORE IN PREDICTING TREATMENT RESPONSE IN A SINGLE UNITED STATES COHORT Ana Marenco-Flores 1 Leandro Sierra 1 Romelia Barba 2 Denisse Rubio-Cruz 1 Daniela Goyes 3 John Esli Medina Morales 4 Tamara Kahan 5 Alan Bonder 1 Vilas Patwardhan 1 , 1 Beth Israel Deaconess Medical Center, 2 Texas Tech University, 3 Yale School of Medicine, 4 Rutgers New Jersey Medical School, 5 Besth Israel Deaconess Medican Center Background: The Ursodeoxycholic Acid Response Score (URS) predicts UDCA therapy response in primary biliary cholangitis (PBC) patients after 12 months of treatment
FRED pose prediction and virtual screening accuracy
In larvae, the free IVM had the lowest larvicidal effect, with LC 50 value of 0.24%
Research suggests the peptide portion serves as more than a carrier, potentially influencing cellular signaling pathways independently of copper delivery [PMID: 29986520]
Clin Orthop Relat Res 1984:303-11
